切换至 "中华医学电子期刊资源库"
高级检索
中华老年病研究电子杂志

中华老年病研究电子杂志 ›› 2026, Vol. 13 ›› Issue (02) : 10 -18. doi: 10.3877/cma.j.issn.2095-8757.2026.02.002

标准与共识

非编码RNA在肾细胞癌液体活检中的应用专家共识
《非编码RNA在肾细胞癌液体活检中的应用专家共识》编写组   
  1. 1. 311121　杭州，浙江大学医学院附属第一医院泌尿外科
  • 收稿日期:2026-02-20 出版日期:2026-05-28
  • 基金资助:
    浙江省"尖兵""领雁"科技计划项目(2024C03165)

Expert consensus on the application of noncoding RNAs in liquid biopsy for renal cell carcinoma

Expert consensus writing group on the application of noncoding RNAs in liquid biopsy for renal cell carcinoma   

  1. 1. 311121 Hangzhou, Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine
  • Received:2026-02-20 Published:2026-05-28
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

《非编码RNA在肾细胞癌液体活检中的应用专家共识》编写组. 非编码RNA在肾细胞癌液体活检中的应用专家共识[J/OL]. 中华老年病研究电子杂志, 2026, 13(02): 10-18.

Expert consensus writing group on the application of noncoding RNAs in liquid biopsy for renal cell carcinoma. Expert consensus on the application of noncoding RNAs in liquid biopsy for renal cell carcinoma[J/OL]. Chinese Journal of Geriatrics Research(Electronic Edition), 2026, 13(02): 10-18.

肾细胞癌（RCC）是泌尿系统常见恶性肿瘤，其早期症状隐匿、异质性强，部分患者术后易复发转移。传统组织活检和影像学检查在动态监测及肿瘤异质性评估方面存在局限性，液体活检具有无创、可重复和可动态检测等优势，已成为精准诊疗的重要研究方向。循环肿瘤细胞、循环肿瘤DNA、外泌体及非编码RNA均为RCC液体活检的重要标志物。其中，环状RNA、长链非编码RNA和微小RNA因稳定性较高、调控功能明确，在RCC诊断、疗效监测及预后评估中显示出较好的应用前景。本文结合国内外最新循证医学证据及临床实践探索，重点围绕非编码RNA在RCC液体活检中的研究现状及临床价值进行梳理和总结，形成5点共识意见，旨在为我国泌尿外科医师防治RCC提供更明确的参考和更规范化的建议，以期进一步提高患者获益。

关键词: 液体活检, 肾细胞癌, 非编码RNA, 生物标志物

Renal cell carcinoma (RCC) is a common malignancy of the urinary system, characterized by insidious early manifestations, marked heterogeneity, and a high risk of postoperative recurrence or metastasis in some patients. Current expert consensus indicates that conventional tissue biopsy and imaging modalities have inherent limitations in dynamic disease monitoring and the assessment of tumor heterogeneity. Due to its minimal invasiveness, repeatability, and capacity for real-time dynamic evaluation, liquid biopsy has become an important focus in precision oncology. Circulating tumor cells, circulating tumor DNA, exosomes, and non-coding RNAs are regarded as key liquid biopsy biomarkers in RCC. Among these, circular RNAs, long non-coding RNAs, and microRNAs have attracted increasing attention because of their relative stability and well-characterized regulatory functions, demonstrating considerable potential in the diagnosis, treatment monitoring, and prognostic assessment of RCC. Based on the latest evidencebased evidence and clinical practice from China and abroad, this consensus summarizes the current research and clinical utility of noncoding RNAs in liquid biopsy for RCC, and formulates five key consensus statements. These are intended to offer Chinese urologists more explicit references and standardized advice for the prevention and treatment of RCC, thereby further enhancing patient benefit.

Key words: Liquid biopsy, Renal cell carcinoma, ncRNA, Biomarker, Expert consensus
[1]
Cochetti G, Guadagni L, Paladini A, et al. An evaluation of serum mirna in renal cell carcinoma: A systematic review[J]. Cancers (Basel), 2025, 17(5):816.
[2]
NCI. Cancer stat facts: Kidney and renal pelvis cancer[EB/OL].[2025-09-26].

URL    
[3]
King SC, Pollack LA, Li J, et al. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010[J]. J Urol, 2014, 191(6):1665-1670.
[4]
Kadeerhan G, Jiang Z, Guo H, et al. Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: An up-to-date overview based on the Global Burden of Disease 2021[J]. Exp Hematol Oncol, 2025, 14(1):103.
[5]
Zhou N, Bai H, Zhang Z, et al. Global, regional, and national burden of kidney cancer and attributable risk factors in adults aged 65 years and older from 1990 to 2021 and projections to 2040[J]. BMC Cancer, 2025, 25(1): 481.
[6]
Hu M, Li Z, Niu Z, et al. Rapidly increasing kidney cancer burden among young adults: Insights from the 1990-2021 Global Burden of Disease Study[J]. BMC Cancer, 2025, 25(1): 1748
[7]
Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3:17009.
[8]
Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours[J]. Eur Urol, 2022, 82(5):458-468.
[9]
Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J]. Ann Oncol, 2024, 35(8):692-706.
[10]
Mao X, Wang G, Wang Z, et al. Theranostic lipid nanoparticles for renal cell carcinoma[J]. Adv Mater, 2025, 37(31):e2306246.
[11]
Motzer RJ, Rane PP, Saretsky TL, et al. Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review[J]. Eur Urol, 2023, 84(4):406-417.
[12]
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger[J]. Ann Oncol, 2019, 30(5):706-720.
[13]
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma[J]. N Engl J Med, 2017, 376(4):354-366.
[14]
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic-implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18(5):297-312.
[15]
朱泓宇，陈露.泌尿系肿瘤液体活检技术新突破[J].上海医学，2025，48(11)：677-682.
[16]
蒋营军，朱绍兴.循环游离DNA在肾细胞癌诊断和预后判断中的作用研究进展[J].浙江临床医学，2020，22(8)：1227-1229.
[17]
来东.基于尿液游离mtDNA的肾细胞癌液体活检应用研究[D].西安：中国人民解放军空军军医大学，2020.
[18]
Hayden JP, Wiggins A, Sullivan T, et al. Use of droplet digital polymerase chain reaction to identify biomarkers for differentiation of benign and malignant renal masses[J]. Cancers (Basel), 2024, 16(4):787.
[19]
Guo W, Chen W, Zhang J, et al. High-throughput methylation sequencing reveals novel biomarkers for the early detection of renal cell carcinoma[J]. BMC Cancer, 2025, 25(1):96.
[20]
Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: Current technology and clinical applications[J]. J Hematol Oncol, 2022, 15(1):131.
[21]
Ye Q, Ling S, Zheng S, et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1):114.
[22]
Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC[J]. J Thorac Oncol, 2018, 13(9):1248-1268.
[23]
Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer[J]. Mol Cancer, 2022, 21(1):114.
[24]
Crocetto F, Barone B, Ferro M, et al. Liquid biopsy in bladder cancer: State of the art and future perspectives[J]. Crit Rev Oncol Hematol, 2022, 170:103577.
[25]
Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of Exosome Composition [J]. Cell, 2019, 177(2):428-445.
[26]
Shah A. The primary role of noncoding RNA in the pathogenesis of cancer[J]. Genes (Basel), 2025, 16(7):771.
[27]
Zhang Q, Fan X, Zhang X, et al. Ferroptosis in tumors and its relationship to other programmed cell death: role of non-coding RNAs[J]. J Transl Med, 2023, 21(1):514.
[28]
Barth DA, Drula R, Ott L, et al. Circulating non-coding RNAs in renal cell carcinoma-pathogenesis and potential implications as clinical biomarkers[J]. Front Cell Dev Biol, 2020, 8:828.
[29]
Ellinger J, Gevensleben H, Muller SC, et al. The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma[J]. Expert Rev Mol Diagn, 2016, 16(10):1059-1065.
[30]
Krishnan S, Kanthaje S, Rekha PD, et al. Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer[J]. Int Rev Cell Mol Biol, 2025, 391:135-197.
[31]
Bolha L, Ravnik-Glavac M, Glavac D. Circular RNAs: Biogenesis, function, and a role as possible cancer biomarkers[J]. Int J Genomics, 2017, 2017:6218353.
[32]
Wang Y, Zhang Y, Wang P, et al. Circular RNAs in renal cell carcinoma: Implications for tumorigenesis, diagnosis, and therapy[J]. Mol Cancer, 2020, 19(1):149.
[33]
Panda AC. Circular RNAs act as miRNA sponges[J]. Adv Exp Med Biol, 2018, 1087:67-79.
[34]
Han D, Li J, Wang H, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression[J]. Hepatology, 2017, 66(4):1151-1164.
[35]
Huang A, Zheng H, Wu Z, et al. Circular RNA-protein interactions: Functions, mechanisms, and identification[J]. Theranostics, 2020, 10(8):3503-3517.
[36]
Du WW, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2[J]. Nucleic Acids Res, 2016, 44(6):2846-2858.
[37]
Song M, Yao H, Sun Z, et al. METTL3/YTHDC1-medicated m6A modification of circRNA3634 regulates the proliferation and differentiation of antler chondrocytes by miR-124486-5-MAPK1 axis[J]. Cell Mol Biol Lett, 2023, 28(1):101.
[38]
Yang Y, Fan X, Mao M, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine[J]. Cell Res, 2017, 27(5):626-641.
[39]
Zhang Y, Wang Y, Su X, et al. The value of circulating circular RNA in cancer diagnosis, monitoring, prognosis, and guiding treatment[J]. Front Oncol, 2021, 11:736546.
[40]
Lu J, Wang YH, Yoon C, et al. Circular RNA circ-RNA GAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis[J]. Cancer Lett, 2020, 471:38-48.
[41]
Zhang N, Nan A, Chen L, et al. Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells[J]. Mol Cancer, 2020, 19(1):101.
[42]
Huang XY, Huang ZL, Huang J, et al. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis[J]. J Exp Clin Cancer Res, 2020, 39(1):20.
[43]
Yang H, Zhang H, Yang Y, et al. Hypoxia induced exosomal circRNA promotes metastasis of colorectal cancer via targeting GEF-H1/RhoA axis[J]. Theranostics, 2020, 10(18):8211-8226.
[44]
Sheng R, Li X, Wang Z, et al. Response to comments on "Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer"[J]. Cancer Lett, 2020, 476:183-184.
[45]
Huang X, Wang J, Guan J, et al. Exosomal circsafb2 reshaping tumor environment to promote renal cell carcinoma progression by mediating M2 macrophage polarization[J]. Front Oncol, 2022, 12:808888.
[46]
Wang Y, Zhang Y, Su X, et al. Circular RNA circDVL1 inhibits clear cell renal cell carcinoma progression through the miR-412-3p/PCDH7 axis[J]. Int J Biol Sci, 2022, 18(4):1491-1507.
[47]
Sun J, Pan S, Cui H, et al. CircRNA SCARB1 Promotes Renal Cell Carcinoma Progression Via Mir- 510-5p/SDC3 Axis[J]. Curr Cancer Drug Targets, 2020, 20(6):461-470.
[48]
Zhang D, Yang XJ, Luo QD, et al. Down-Regulation of circular RNA_000926 attenuates renal cell carcinoma progression through miRNA-411-Dependent CDH2 Inhibition[J]. Am J Pathol, 2019, 189(12):2469-2486.
[49]
Liu H, Hu G, Wang Z, et al. circPTCH1 promotes invasion and metastasis in renal cell carcinoma via regulating miR-485-5p/MMP14 axis[J]. Theranostics, 2020, 10(23):10791-10807.
[50]
Feng J, Guo Y, Li Y, et al. Tumor promoting effects of circRNA_001287 on renal cell carcinoma through miR-144-targeted CEP55[J]. J Exp Clin Cancer Res, 2020, 39(1):269.
[51]
Cen J, Liang Y, Huang Y, et al. Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis[J]. Mol Cancer, 2021, 20(1):19.
[52]
Li K, Wan CL, Guo Y. Circular RNA circMTO1 suppresses RCC cancer cell progression via miR9/LMX1A axis[J]. Technol Cancer Res Treat, 2020, 19:1533033820914286.
[53]
Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells[J]. Oncol Lett, 2019, 18(5):4393-4402.
[54]
Chen T, Lu J, Fan Q. lncRNA TUG1 and kidney diseases[J]. BMC Nephrol, 2025, 26(1):139.
[55]
Chen C, Luo Y, He W, et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer[J]. J Clin Invest, 2020, 130(1):404-421.
[56]
Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J]. Cancer Cell, 2016, 29(5):653-668.
[57]
Wu Y, Wang YQ, Weng WW, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls[J]. Oncogenesis, 2016, 5(2):e192.
[58]
He ZH, Qin XH, Zhang XL, et al. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1):46-54.
[59]
Xie J, Zhong Y, Chen R, et al. Serum long non-coding RNA LINC00887 as a potential biomarker for diagnosis of renal cell carcinoma[J]. FEBS Open Bio, 2020, 10(9):1802-1809.
[60]
Yu Y, Niu YY, Zhang YY, et al. Urinary long non-coding RNA GAS5 as a noninvasive diagnostic biomarker for renal fibrosis[J]. Ren Fail, 2025, 47(1):2534493.
[61]
Sharma D, Singh A, Wilson C, et al. Exosomal long non-coding RNA MALAT1: A candidate of liquid biopsy in monitoring of Wilms' tumor[J]. Pediatr Surg Int, 2024, 40(1):57.
[62]
Pan Y, Lu X, Shu G, et al. Extracellular vesicle-mediated transfer of lncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma[J]. Cancer Res, 2023, 83(1):103-116.
[63]
Miranda-Poma J, Trilla-Fuertes L, Lopez-Camacho E, et al. MiRNAs in renal cell carcinoma[J]. Clin Transl Oncol, 2022, 24(11):2055-2063.
[64]
Ma L, Guo H, Zhao Y, et al. Liquid biopsy in cancer current: Status, challenges and future prospects[J]. Signal Transduct Target Ther, 2024, 9(1):336.
[65]
Heinemann FG, Tolkach Y, Deng M, et al. Serum miR-122-5p and miR-206 expression: Non-invasive prognostic biomarkers for renal cell carcinoma[J]. Clin Epigenetics, 2018, 10:11.
[66]
Tusong H, Maolakuerban N, Guan J, et al. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma[J]. Cancer Biomark, 2017, 18(1):79-85.
[67]
Xue Y, Chen T, Hou N, et al. Serum extracellular vesicles derived hsa-miR-320d as an indicator for progression of clear cell renal cell carcinoma[J]. Discov Oncol, 2023, 14(1):114.
[68]
Chen X, Li R, Li X, et al. Identification of a four-microRNA panel in serum for screening renal cell carcinoma[J]. Pathol Res Pract, 2021, 227:153625.
[69]
Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma[J]. J Transl Med, 2012, 10:55.
[70]
Wang C, Hu J, Lu M, et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma[J]. Sci Rep, 2015, 5:7610.
[71]
Lou N, Ruan AM, Qiu B, et al. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma[J]. Urol Oncol, 2017, 35(1):36.e7-36.e14.
[72]
Zhang W, Ni M, Su Y, et al. MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma[J]. Eur Urol Focus, 2018, 4(3):412-419.
[73]
He J, He J, Min L, et al. Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma[J]. Int J Cancer, 2020, 146(4):1052-1063.
[74]
Aveta A, Cilio S, Contieri R, et al. Urinary microRNAs as biomarkers of urological cancers: A systematic review[J]. Int J Mol Sci, 2023, 24(13):10846.
[75]
Li G, Zhao A, Peoch M, et al. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma[J]. Urol Oncol, 2017, 35(5):294-299.
[76]
Cochetti G, Cari L, Nocentini G, et al. Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma[J]. Sci Rep, 2020, 10(1):21290.
[77]
Fedorko M, Juracek J, Stanik M, et al. Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma[J]. Biochem Med (Zagreb), 2017, 27(2):411-417.
[78]
Borges Dos Reis R, Shu X, Ye Y, et al. Urinary miRNAs predict metastasis in patients with clinically localized clear cell renal cell carcinoma treated with nephrectomy[J]. Clin Genitourin Cancer, 2024, 22(1):e156-e162.
[79]
Outeiro-Pinho G, Barros-Silva D, Aznar E, et al. MicroRNA-30a-5p(me): A novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples[J]. J Exp Clin Cancer Res, 2020, 39(1):98.
[80]
Lv C, Zhong Y, Hu Y, et al. Potential liquid biopsy markers of exosomal microRNAs in renal interstitial fibrosis blood and urine[J]. Indian J Pathol Microbiol, 2025, 68(2):279-286.
[1] 江鸿宇, 梁家洛, 马琳, 邓永强, 李星瀚. 口腔和口咽鳞状细胞癌免疫治疗相关生物标志物研究现状[J/OL]. 中华口腔医学研究杂志(电子版), 2026, 20(02): 136-148.
[2] 陈劲松, 雷雪涛, 董毅. 免疫检查点抑制剂在胃癌治疗中的应用现状[J/OL]. 中华普通外科学文献(电子版), 2026, 20(03): 200-206.
[3] 甄旭, 司睿, 郭宏骞, 纪长威. SHOX2高表达与pT1期非透明细胞肾细胞癌淋巴结转移及不良预后的相关性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(04): 451-457.
[4] 张俊峰, 牛越, 陈鹏. 局部进展期肾细胞癌新辅助和辅助治疗策略的现实挑战与未来发展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(03): 248-254.
[5] 陈宇煊, 方建雄, 曹嘉正. 基于DNA甲基化、基因突变及转录组的尿液基因组学检测在尿路上皮癌诊断中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(03): 341-345.
[6] 陈惠姗, 曾惠清. 生物标志物在诊断渗出性和漏出性胸腔积液鉴别诊断中的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 330-334.
[7] 陈力, 高心怡, 刘心怡, 邵幼林. 血清降钙素原在社区获得性肺炎严重程度评估及抗生素使用指导中的临床应用研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 341-345.
[8] 姚平, 顾翔, 韩静, 杨苗苗, 沈鑫, 孙建, 戚小艳. 血清糖链抗原6和肺表面活性蛋白D预测221例结缔组织病相关间质性肺病及严重程度的研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 253-261.
[9] 刘国臣, 安嘉伟, 朱俊宇, 代伟宏, 李芬. LCN2在脓毒症中的作用机制研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(03): 162-169.
[10] 王泽宁, 费振浩, 陈业盛, 孙志为. 基于肝癌体积-时间窗的个体化TACE-MWA序贯治疗策略及其机制探讨[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(03): 307-316.
[11] 傅书强, 王宏刚. 液体活检主要生物标志物在结直肠癌中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 274-281.
[12] 杨悦, 张正威. 光学相干断层扫描成像中脉络膜高反射灶的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2026, 16(01): 54-58.
[13] 伍宵, 唐颖, 张曦文, 邱海波. 表观遗传修饰调控急性呼吸窘迫综合征发病机制的研究进展[J/OL]. 中华重症医学电子杂志, 2026, 12(02): 202-207.
[14] 姜秀文, 戴璇, 周旻, 张圆, 何媛, 顾乃刚. 慢阻肺病并发肾损伤的机制及早期诊断生物标志物的研究进展[J/OL]. 中华临床医师杂志(电子版), 2026, 20(05): 374-380.
[15] 林烨涛, 黄浩淇, 徐穗莲, 古媚, 何奕涛. 环状RNA对缺血性卒中调控作用的研究进展[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(06): 538-545.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？